Peregrine Pharma shares skyrocket; Roche chairman sours on Illumina bid;

 @FierceBiotech: Indian supreme court: Unregulated trials causing 'havoc'. More | Follow @FierceBiotech

@JohnCFierce: As Big Pharma falters, Big Biotech helps fill a $100B "gap." Editor's Corner | Follow @JohnCFierce

@RyanMFierce: Boehringer doesn't want $LLY's basal insulin analog anymore, amends big diabetes pact. News | Follow @RyanMFierce

> Roche's ($RHHBY) chairman shot down chances of his company mounting another effort to acquire Illumina ($ILMN). Item

> Peregrine Pharmaceuticals ($PPHM) shares soared more than 60% on Monday on the back of news that its review of data from a midstage study of its candidate bavituximab in patients with non-small cell lung cancer has encouraged the company to advance the drug into Phase III development. Item

> Merck ($MRK) says that the FDA has accepted its resubmitted NDA for its contender called sugammadex for reversing neuromuscular blockade. Item

> Vertex ($VRTX) updated on key programs in hepatitis C and cystic fibrosis and plans for 2013. Release

Medical Device News

 @FierceMedDev: Johnson & Johnson's first vaginal mesh trial revs up this week. More | | Follow @FierceMedDev

@MarkHFierce: Illumina is grabbing Verinata Health for $350M-plus. The buy gets it into fetal Dx business. Story | Follow @MarkHFierce

 @DamianFierce: Unregulated clinical trials are wreaking "havoc" in India, the supreme court says. News | Follow @DamianFierce

> SeraCare refocuses energies on in vitro Dx work. Item

> EndoChoice grabs $45M to back merger with Israeli GI startup. Story

Pharma News

@FiercePharma: Eli Lilly's 2013 profits forecast surpasses analyst predictions. What gives? More | Follow @FiercePharma

 @AlisonBFierce: What's the buzz? Big Pharma may be on the verge of a buying spree. News | Follow @AlisonBFierce

> Roche chairman pooh-poohs another Illumina bid. Report

> Valeant chief shoots for $10B in sales--and then $20B. Story

Biotech IT News

> Quants collaborate on forecasting value of genomics in medicine. Story

> Is FDA keeping social media from taking flight in pharma? Editor's Corner

> Abbott spinoff AbbVie starts social media effort from scratch. Article

> Agilent unit picks up lab software rights to fuel cancer diagnostics biz. News

CRO News

> WCCT partners with U.S.'s largest trial registry on patient adherence. Article

> Questcor snags CMO BioVectra for $50.7M. News

> Cellular Dynamics signs on with AstraZeneca for drug discovery. Story

> Indian Supreme Court: Unregulated trials causing 'havoc'. Report

> Clinical Network Services buys CRO Beltas. Item

And Finally… Health insurers, not as much the FDA, give biotech chiefs the jitters. Column





Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.